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Objective: The DiaMind trial showed beneﬁcial immediate effects of mindfulness-based cognitive therapy
(MBCT) on emotional distress, but not on diabetes distress and HbA1c. The aim of the present report was to
examine if the effects would be sustained after six month follow-up.
Methods: In the DiaMind trial, 139 outpatients with diabetes (type-I or type-II) and a lowered level of emotional
well-being were randomized into MBCT (n = 70) or a waiting list with treatment as usual (TAU: n = 69).
Primary outcomes were perceived stress, anxiety and depressive symptoms, and diabetes distress. Secondary
outcomes were, among others, health status, and glycemic control (HbA1c).
Results: Compared to TAU, MBCT showed sustained reductions at follow-up in perceived stress (p b .001, d =
.76), anxiety (p b .001, assessed by HADS d= .83; assessed by POMS d= .92), and HADS depressive symptoms
(p= .004, d= .51), but not POMS depressive symptoms when using Bonferroni correction for multiple testing
(p= .016, d= .48). No signiﬁcant between-group effect was found on diabetes distress and HbA1c.
Conclusion: This study showed sustained beneﬁts of MBCT six months after the intervention on emotional
distress in people with diabetes and a lowered level of emotional well-being.
Trial registration: Dutch Trial Register NTR2145, http://www.trialregister.nl.© 2014 Elsevier Inc. All rights reserved.Introduction
The prevalence of emotional distress in people with diabetes is rela-
tively high (i.e., diabetes-speciﬁc emotional distress approximately
18%[1], anxiety symptoms approximately 40%[2] and depressive symp-
toms 20–40%[1,3]) and is associated with negative outcomes, such as
lower quality of life, suboptimal self-care behaviors and glycemic control,
risk of adverse cardiovascular outcomes, and higher mortality rates
[4–8]. A newpromising psychological intervention in peoplewith diabe-
tes with emotional problems is themindfulness-based cognitive therapy
(MBCT) program. It has been used in various chronically ill populations,
effectively decreasing feelings of distress, anxiety, and depression [9]. A
previous report from the current study showed that MBCT, immediately
at post intervention, was associated with a signiﬁcant reduction in per-
ceived stress, anxiety and depressive symptoms in people with diabetes
and lowered level of emotional well-being [10]. However, it is yet un-
clear if the beneﬁcial effects are sustained over a longer period of time.LE Tilburg, The Netherlands.
klíček).One randomized trial in cancer patients did notﬁnd sustained effects
of MBCT on perceived stress, anxiety or depressive symptoms after six
month follow-up [11], while other studies in different patient groups
did show maintained improvements in psychological distress after six
or twelve months [12–14]. In people with type-II diabetes, only one
previous study reported longer-term outcomes. That study showed an
effect on levels of depression one year after the intervention [15], al-
though no sustained effects were found on levels of stress. The present
study attempts to extend these ﬁndings by also including people with
type-I diabetes and to examine the effect on symptoms of anxiety and
diabetes-speciﬁc distress.
Method
The Diabetes and Mindfulness (DiaMind) study design, a random-
ized controlled trial (approved by the Medical Ethics Committee of the
St. Elisabeth Hospital in Tilburg) has been discussed in detail elsewhere
[16]. Adults with diabetes (type 1 or type 2) with low levels of emotion-
al well-being (as evidenced by a score of b13 on theWHO-5 well-being
Index) were recruited from outpatient diabetes clinics. Eligible patients
who agreed to participate (n= 139) were randomized to a waiting list,
treatment-as-usual, (TAU: n = 69) or to an MBCT group (n = 70),
Table 1
Demographic and clinical characteristics of MBCT and TAU group
MBCT
(n = 70)
TAU
(n = 69)
pa
Mean age, years (SD) 56 (13) 57 (13) .62
Male, n (%) 33 (47) 37 (54) .45
High educationb, n (%) 31 (44) 28 (41) .66
Working, n (%) 28 (40) 19 (28) .12
Living with a partner, n (%) 51 (73) 53 (77) .59
Diabetes type 2, n (%) 52 (74) 45 (65) .41
MBCT—mindfulness-based cognitive therapy group; TAU—waiting list (usual care) con-
trol group.
a Chi-square for nominal variables and t-test for continuous variables.
b High education: high-level vocational education and university.
82 J. van Son et al. / Journal of Psychosomatic Research 77 (2014) 81–84consisting of eight weekly two-hour group sessions [17]. Three months
after the end of the intervention a two-hour booster session had beenFig. 1. Flow diagram of patient enrolment, allocation, and attrition. MBCT—mindfulness-based
baseline assessment; T2—post intervention assessment; T3— sixmonths follow-up assessment
the consecutive time points.added. The assessment of the outcomes took place at pre- (T1) and
post intervention (T2), and after 6 months post intervention (T3). De-
mographic and clinical variables (e.g., existence of diabetes complica-
tions and co-morbid conditions) were assessed at baseline using
questionnaires, except for HbA1c values (the amount of glycated hemo-
globin in blood) which were evaluated by chart review.
Emotional distress was the primary outcome, deﬁned as symptoms of
anxiety, depression and (diabetes-speciﬁc) stress [18]. The 10-item Per-
ceived Stress Scale (PSS) (5-point Likert scale) [19] and the Hospital Anx-
iety (7-items) and Depression (7-items) Scale (HADS) (4-point Likert
scale) [20], and the Proﬁle of Mood States (POMS) (5-point Likert scale)
[21] were used, as well as the 20-items ProblemAreas in Diabetes Survey
(PAID) to assess diabetes speciﬁc stress (six-point Likert scale) [22].
For secondary outcomes the following questionnaires were used:
Short-Form Health Survey (SF-12) [23], Five Facet Mindfulness Ques-
tionnaire (FFMQ) (except for the subscale Describing) [24], Acceptancecognitive therapy intervention group; TAU—waiting list (usual care) control group. T1—
. The lost to follow-upnumbers of T2 andT3 each show the total number lost to follow-up at
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Self-Esteem Scale (RSES) [26]. Because our primary outcome of interest
was emotional distress, the status of the variables ‘diabetes distress’ and
‘health status’was changed from respectively secondary and primary as
registered originally (Netherlands Trial Registry 2145) to respectively
primary and secondary [16]. In addition, we also decided to (i) include
people with type 1 diabetes to be able to examine the broader applica-
bility of the intervention, and (ii) not measure heart rate variability to
prevent loss of participants due to complex daily measurements [16].
Data analyses
SPSS linear regression analyses on change scores (T3–T1) were used
to test the differences between groups on the dependent variables. All
analyseswere based on the intention-to-treat approach.Multiple impu-
tation (20 imputations using the Predictive MeanMatching procedure)
was used to addressmissing data. Given the analysis of six primary out-
come measures and subsequent higher risk of a type I error, the alpha
level for signiﬁcance was set at 0.008 for the main analyses (Bonferroni
correction of alpha of 0.05 divided by 6). Sensitivity analyses included
mixed models analyses using all three time points without imputed
missing values.
Cohen's d effect sizeswere calculated on themean change scores be-
tween T1 and T3 of the two conditions, with the following formula
(MMBCT−MTAU) / σpooled. A Cohen's d between 0.2 and 0.5 indicates a
small effect, between 0.5 and 0.8 a moderate effect, and larger than
0.8 a large effect [27].
Results
There were no signiﬁcant differences between the MBCT and TAU group on baseline
variables (Table 1, see also prior article [10]). Fig. 1 shows the ﬂow of participants during
the study. Participants of both conditions who did not ﬁll in the T3 measurement, were
younger (p = .013), had a lower BMI (p = .006), and a higher score on the HADS-A
(p = .013) at baseline. In the MBCT group, 59% of the participants attended at least 6 ofTable 2
Mean (SD) scores and results of linear regression analyses
Measure Pre M (SD) Post M
Primary outcomes
Perceived stress MBCT 19.5 (6.0) 14.4 (7
TAU 20.4 (5.9) 19.0 (6
HADS-anxiety MBCT 8.6 (3.3) 6.7 (3
TAU 9.4 (3.6) 8.8 (4
POMS-anxiety MBCT 20.5 (4.5) 17.4 (4
TAU 20.2 (4.4) 19.8 (5
HADS-depression MBCT 8.2 (3.8) 5.6 (4
TAU 9.2 (3.9) 8.6 (4
POMS-depression MBCT 25.3 (5.8) 21.4 (4
TAU 26.7 (6.3) 26.2 (7
Diabetes distress MBCT 35.5 (17.8) 28.7 (2
TAU 36.6 (18.9) 33.5 (2
Secondary outcomes
HbA1c mmol/mol MBCT 59.0 (12.6) 59.3 (1
% 7.5 (1.2) 7.5 (1
mmol/mol TAU 59.2 (13.0) 61.7 (1
% 7.6 (1.2) 7.9 (1
Mental health status MBCT 32.8 (11.0) 41.1 (1
TAU 31.7 (11.6) 35.0 (1
Physical health status MBCT 39.4 (9.9) 40.7 (1
TAU 37.4 (11.4) 36.6 (1
Mindfulness MBCT 96.2 (13.8) 104.6 (1
TAU 94.3 (12.4) 96.6 (1
Diabetes acceptance MBCT 58.4 (8.6) 60.3 (8
TAU 58.2 (7.2) 58.7 (7
Self-esteem MBCT 18.6 (5.4) 21.4 (5
TAU 15.9 (5.4) 17.4 (5
MBCT—mindfulness-based cognitive therapy group; TAU—waiting list (usual care) control g
a The effect size (Cohen's d) was calculated on pre to six month follow-up intervention chanthe 8 sessions (overall mean attendance was 5.5 ± 2.5 sessions) and 30% attended the
booster session three months after the end of the intervention.
Linear regression analysis showed a signiﬁcant effect of MBCT on perceived stress
from baseline to six month follow-up compared to TAU (p b .001). The effect size of
the difference from T1 to T3 between the two groups was moderate to large (Cohen's
d = .76) (Table 2). Post hoc analyses revealed that there was no signiﬁcant difference be-
tween the groups in perceived stress change scores from post-intervention to six month
follow-up (p = .49), indicating a stable effect of the intervention. In addition, in the
MBCT group a signiﬁcantly larger reduction in depressive symptoms (HADS) from base-
line to six months was found (p = .004), with a medium effect size (Cohen's d = .51),
although when assessed by the POMS, this did not reach the Bonferroni corrected level
of signiﬁcance (p = .016, d= .48) (Table 2). Post hoc analyses did not reveal signiﬁcant
changes in depressive symptoms from post-intervention to sixmonth follow-up between
groups (p N .10). Also, theMBCT group showed a larger decrease on symptoms of anxiety
over time for both HADS and POMS (p b .001). The effect size was large in both cases
(Cohen's d N .80) (Table 2). No signiﬁcant changes in anxiety symptoms appeared from
post-intervention to follow-up (p ≥ .09). There was no signiﬁcant difference between
MBCT and TAU on change in diabetes distress (p= .034, Cohen's d= .41) from T1 to T3
(Table 2).
Regarding secondary outcomes, signiﬁcant differences between the groups in change
scores were found only for mental health status and mindfulness, not for the other vari-
ables (Table 2), including HbA1c (p = .82; Cohen's d = .06). Sensitivity analyses based
on mixed models using all time points yielded similar results (e.g., all signiﬁcant results
mentioned above were also signiﬁcant with similar effect sizes).
Discussion
The present paper shows that the reduction in perceived stress,
anxiety and depressive symptoms in the MBCT group was sustained
six months after the intervention (all medium to large effect sizes),
although in the case depressive symptoms were assessed by POMS,
the Bonferroni corrected p-value failed to reach signiﬁcance.
In correspondence with the results that were found immediately at
post intervention [10], there was no effect of MBCT on diabetes distress
and glycemic control after follow-up. Since only a minority of the partic-
ipants in the present sample (48%) experienced elevated diabetes dis-
tress (PAID ≥ 40) and the mean baseline HbA1c value of the two
groups appeared to be already fairly good (59 mmol/mol, SD = 13; in(SD) 6-m FU M (SD) Effect Group on Pre-to-6-m FU change
t p da
.1) 13.4 (6.7) −3.93 b .001 0.76
.7) 18.9 (7.0)
.6) 5.4 (3.1) −4.24 b .001 0.83
.1) 8.8 (3.9)
.1) 16.4 (3.4) −4.43 b .001 0.92
.1) 19.4 (5.0)
.0) 5.2 (3.6) −2.89 .004 0.51
.7) 8.2 (4.5)
.5) 21.8 (4.7) −2.41 .016 0.48
.0) 25.7 (7.3)
1.0) 25.0 (19.7) −2.12 .034 0.41
2.0) 32.8 (20.1)
2.1) 59.2 (11.7) −0.23 .816 0.06
.1) 7.6 (1.1)
6.4) 60.6 (16.2)
.5) 7.7 (1.5)
0.7) 42.5 (10.3) 4.24 b .001 0.77
2.5) 33.9 (11.7)
0.5) 40.4 (10.8) 2.12 .034 0.40
1.7) 35.6 (13.0)
7.0) 108.2 (15.7) 3.46 .001 0.64
4.1) 98.1 (13.5)
.3) 60.6 (8.5) 1.62 .105 0.32
.5) 58.2 (7.1)
.3) 20.9 (5.7) 0.53 .597 0.11
.4) 17.7 (6.0)
roup.
ge scores.
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≤64 [28]) [10], the non-signiﬁcant ﬁndings could be caused by ﬂoor ef-
fects. Future research on the effect of MBCT on diabetes distress and
HbA1c should focus on people with poor glycemic control and elevated
diabetes distress at baseline.
The follow-up results of the present study are encouraging. The
MBCT group maintained their gains over a period of six months with
no to minimal further intervention (only 30% of the MBCT participants
attended the booster session three months after the intervention),
which corresponds with most of the few studies that have examined
longer-term effectiveness ofmindfulness-based intervention inmedical
patients [12,13,15]. In addition, the results are similar to the results of
the few studies on long-term effectiveness of cognitive (behavioral)
therapy on depressive symptoms [29], but more research is needed.
This studyhad several limitations. First,we had nodata on (the qual-
ity/quantity of) home mindfulness practice after the intervention.
Therefore, we could not distinguish the effect in the group who contin-
ued mindfulness practice after the intervention and the group who did
not. Second, there was a considerable drop-out rate in the MBCT group.
Around a quarter of the participants (n = 18) stopped with the pro-
gram, which however is in line with previous studies in somatic patient
groups [11,30]. Third, we had no a priori plan for statistical adjustment
considering the multiple primary outcomes, and ﬁnally, the use of a
waiting list control group may have overestimated effect sizes due to
the inclusion of non-speciﬁc treatment effects in the relative improve-
ment of the MBCT group.
In conclusion, the current study showed sustained effectiveness of
MBCT in reducing emotional distress for participants with diabetes
and a lowered level of emotional well-being. Because emotional distress
is related to poor diabetic outcome, MBCT might be an important addi-
tional strategy in adequately treating people with diabetes.
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